Belite Bio, Inc. ADR Quality Score
BLTE
Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.
Broad-market heuristics · Not a buy/sell signal
Valuation and growth
Valuation
Growth
Negative earnings, no valuation support
Negative FCF, no valuation support
FCF negative, burning cash after capex
Business Quality & Capital Allocation
Heavy dilution above 5%
Net cash position, no leverage concern
Below 8%, may not cover cost of capital
Belite Bio, Inc. ADR (BLTE) quality: score, margins and returns
Belite Bio, Inc. ADR (BLTE) scores 10/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 4 metrics each scored 0 to 100 and -14.5% ROIC. Every metric is computed from company filings; this is analysis, not investment advice.
Frequently asked
Is Belite Bio, Inc. ADR (BLTE) a high-quality business?+
Belite Bio, Inc. ADR scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Recent figures include a -14.5% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.
What does Belite Bio, Inc. ADR's quality score measure?+
Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from BLTE's company filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Belite Bio, Inc. ADR scores well and where it falls behind.
What is Belite Bio, Inc. ADR's return on invested capital (ROIC)?+
Belite Bio, Inc. ADR earns about -14.5% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to BLTE's margins and growth on this scorecard to judge durability.
Peers
Biotechnology · Pick stocks to compare with BLTE
Held by ETFs
BLTE is in 7 US ETFs. The largest of them, with BLTE's weight in each:
SPDR Portfolio Emerging Markets ETFSPEM0.03%of the fund
Fidelity Nasdaq Composite Index ETFONEQ0.01%of the fund
- APActivePassive International Equity ETFAPIE0.06%of the fund
SPDR S&P China ETFGXC0.11%of the fund
- EHEven Herd Long/Short ETFEHLS0.33%of the fund
- BBVirtus Biotech Clinical Trials ETFBBC0.77%of the fund
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing BLTE
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.